Compare iShares MSCI Canada (TSX) (EWC) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Canada (TSX) vs ResMed Inc. — how do they compare? iShares MSCI Canada (TSX) trades at $61.65, while ResMed Inc. trades at $225.34 (market cap $32.61B). The key difference: ResMed Inc. pays a 1.17% dividend while iShares MSCI Canada (TSX) pays none, and iShares MSCI Canada (TSX) is trading nearer its 52-week high, ResMed Inc. nearer its low. Which is the better fit depends on your goals.
| EWC | RMD | |
|---|---|---|
Sector | Broad Market / Factor | Health |
52-Week High | $61.51 | $293.73 |
52-Week Low | $47.00 | $182.82 |
Market Cap | — | $32.61B |
Enterprise Value | — | $31.97B |
Dividend Yield | — | 1.17% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWC trades at $61.81, up 0.5% on the day, with a bullish technical signal driven by moving averages but caution from overbought RSI levels. The ETF shows strong performance in 2026 with double-digit returns, though it trails the S&P 500. Recent news highlights trade tensions with the U.S., including potential 50% tariffs on Canadian goods, but key exclusions may limit material impact.
Outlook remains cautiously optimistic due to Canada's economic resilience and active ETF market growth. Risks include trade war escalation and commodity price volatility, but analyst sentiment supports bullish positioning for diversified exposure to Canadian equities.
ResMed (RMD) trades at $221.22, up 0.53% with a bullish technical signal and strong fundamental performance. The company delivered four consecutive quarterly earnings beats, with Q4 2026 EPS of $2.95 beating expectations by 2.1%. Revenue grew 9% year-over-year to $1.5 billion, while maintaining robust profitability with 61.1% gross margins and 26.9% net income margins. Recent strategic moves include the $490 million sale of MatrixCare to focus on core sleep and respiratory care markets.
The stock presents a compelling growth story with consistent execution, though near-term headwinds from weak 2027 revenue guidance create uncertainty. Analyst consensus targets $235.00 (6.2% upside) with 40% buy ratings. Key risks include ventilator sales suspension, cost pressures, and competitive threats in the medical device space. The company's strong cash flow generation and shareholder returns ($1.0 billion in 2026) support long-term value creation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About iShares MSCI Canada (TSX)
EWC is a country-specific ETF that tracks the performance of the Canadian equity market. It provides exposure to large and mid-sized companies in Canada, with heavy concentrations in financials and energy, including Royal Bank of Canada, Shopify, and Enbridge.
Read more on EWC →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
